Michael Robin Witt
Vorstandsvorsitzender bei GABATHER AB
Profil
Michael Robin Witt is the founder of Axcentua Pharmaceuticals AB, which was founded in 2007.
He held the position of Chief Scientific Officer from 2010 to 2012.
Currently, he is the Chief Executive Officer & Director at Gabather AB since 2014 and the Chief Executive & Scientific Officer at Lead Discovery Malaysia Sdn.
Bhd.
since 2012.
In the past, he worked as a Principal Scientist at Karo Healthcare AB, a Project Leader at NTG Nordic Transport Group A, and a Principal at AstraZeneca AB.
Dr. Witt has a graduate and doctorate degree from Vrije Universiteit Brussel and a doctorate degree from Danmarks Farmaceutiske Universitet.
Aktive Positionen von Michael Robin Witt
| Unternehmen | Position | Beginn |
|---|---|---|
| GABATHER AB | Vorstandsvorsitzender | 01.10.2018 |
| Lead Discovery Malaysia Sdn. Bhd. | Vorstandsvorsitzender | 01.01.2012 |
Ehemalige bekannte Positionen von Michael Robin Witt
| Unternehmen | Position | Ende |
|---|---|---|
Axcentua Pharmaceuticals AB
 Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Gründer | 01.04.2012 |
| KARO PHARMA AB (PUBL) | Technik-/Wissenschafts-/F&E-Leiter | - |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Corporate Officer/Principal | - |
| NTG NORDIC TRANSPORT GROUP A/S | Corporate Officer/Principal | - |
Ausbildung von Michael Robin Witt
| Vrije Universiteit Brussel | Doctorate Degree |
| Danmarks Farmaceutiske Universitet | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| KARO PHARMA AB (PUBL) | Health Technology |
| NTG NORDIC TRANSPORT GROUP A/S | Transportation |
| GABATHER AB | Health Technology |
| Private Unternehmen | 3 |
|---|---|
AstraZeneca AB
AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden. | Commercial Services |
Axcentua Pharmaceuticals AB
Axcentua Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Axcentua Pharmaceuticals AB develops anti-cancer drugs for pancreatic cancer patients. It generates investigational new drugs for diseases with unmet medical need in Sweden. The firm offers AXP107-11, multi-targeted chemosensitizer and a small-molecule anti-cancer compound for the treatment of various solid tumors, such as non-small cell lung cancers. The company was founded in 2007 by Anders Berkenstam, Stefan Rehnmark and Michael-Robin Witt and is headquartered in Stockholm, Sweden. | Health Technology |
| Lead Discovery Malaysia Sdn. Bhd. |
